Financings Roundup
Ready for 'Pivotal' Year, Array Adds $52M in Public Offering
With data from at least seven clinical trials due this year, along with a Phase III go/no-go decision on its most advanced partnered program, Array Biopharma Inc. is bolstering its cash position with a $52 million public offering.